http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102327219-B
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e328f3403a32b1dbb56db1d343f262f5 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-28 |
filingDate | 2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2013-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5162cebd8e673a9e453a73eb340a9deb |
publicationDate | 2013-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CN-102327219-B |
titleOfInvention | Solid esomeprazole magnesium lipidosome preparation |
abstract | The invention relates to a solid esomeprazole magnesium lipidosome preparation and a preparation method thereof. The solid esomeprazole magnesium lipidosome preparation is characterized by mainly comprising the following components according to weight part: 20 parts of esomeprazole magnesium, 50-100 parts of soybean lecithin, 50-150 parts of distearoyl phosphatidylglycerole, 50-150 parts of cholesterol and 150-200 parts of other general pharmaceutical excipients. According to the invention, the solid esomeprazole magnesium lipidosome preparation is prepared by adopting a reverse phase evaporation method, thus the bioavailability and the stability of the esomeprazole magnesium are greatly improved, toxic or side effects are greatly reduced, the quality of a preparation product and the curative effect is improved and the convenience for the clinical application is greatly realized. |
priorityDate | 2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.